ORE than 240,000 new cases of breast cancer are diagnosed each year and one of every eight women will suffer from breast cancer in her lifetime. Breast cancer ranks second among deaths from cancer in women, with an estimated 41,000 deaths each year. Brain metastases from breast cancer occur in approximately 10% of patients, 2 a rate second only to lung metastases. The presence of intracranial lesions is considered an inauspicious prognostic indicator.
planning easier. Breast cancer is considered to be a radiosensitive tumor, and the use of GKS on intracranial lesions with this histological diagnosis seems logical. Our philosophy for selecting patients to undergo GKS remains driven by multiple factors. Lesions in deep, surgically inaccessible locations, few metastatic deposits (usually Յ three), and lesions in which all the dimensions are less than 3 cm are some of the criteria. We have treated a greater number of lesions when the patient presents with very good performance status and when the brain is the only site of treatment failure. Impending neurological deficits will usually result in a recommendation for neurosurgical intervention, unless precluded by the deep location of the lesion, in which case an aggressive steroid regimen and GKS is offered. Treatment failures associated with GKS are first treated with GKS again and, on further failure, treated by open surgery if feasible-with the understanding that these patients perhaps harbor aggressive clonogenic tumors that are unlikely to respond well to any management strategy.
The purpose of this study was to analyze results in patients with intracranial lesions from breast cancer who were treated with GKS and to identify prognostic factors associated with survival.
Clinical Material and Methods

Patient Population
Forty-three patients with breast carcinoma harbored 84 metastatic deposits in the brain and were treated with GKS at the University of Virginia Health System between 1989 and 2000. Of the 43 patients who underwent GKS, 35 underwent one treatment, two underwent radiosurgery twice for the same lesion, and six patients underwent GKS for new lesions at a later date. The mean age of these patients at the time of treatment was 51 years (range 32-92 years). The KPS score at the time of treatment was 100 in 12% of the patients, 90 in 53%, 80 in 33%, and 40 in 2% of the patients. Thirty-five patients (81%) were Caucasian, whereas eight (19%) were African-American. Thirty patients (70%) received WBRT before they underwent GKS. Five of these patients underwent GKS as a salvage procedure after failure of WBRT, whereas the others received boosts from the Gamma Knife as a planned treatment strategy. Neurological symptoms were present in 95% of the patients (Table 1) .
Tumor Characteristics
Seventeen patients (40%) harbored one lesion, 13 (30%) two lesions, nine (21%) three lesions, three (7%) four lesions, and one (2%) five lesions that were treated using GKS. In 21 patients (51%) the dominant lesions were located in the cerebellum. The mean volume of the lesions before GKS was 4.1 cm 3 (range 0.80-4.68 cm 3 ), and the mean volume of the lesions after GKS was 2.6 cm 3 (range 0.48-2.1 cm 3 ) ( Table 2) .
Treatment Parameters
Gamma knife surgery was performed using the Leksell Gamma Knife unit (model U; Elekta Instruments, Inc., Norcross, GA). The source output for the unit during the study period varied between 329.7 and 161 cGy/minute for those patients treated before 60 Co reloading in October 1995 and between 340.5 and 239.6 cGy/minute for those treated after 60 Co reloading. The mean maximal radiation dose delivered to a tumor was 51.18 Gy (range 45-60 Gy). The mean minimal radiation dose delivered to a tumor was 17.9 Gy (range 17.5-18.5 Gy). The mean number of isocenters was 2.2 (range one-eight) ( Table 2) .
Follow-Up Evaluation
Clinical follow-up data were available in all 43 patients (84 treated lesions). The follow-up evaluation included neuroimaging studies (CT or MR imaging) every 3 months for the first 2 years, with biannual examinations thereafter. Nine patients with a total of 16 lesions died within the first 3 months after GKS, before they were scheduled for the first follow-up imaging study. An assessment of the neuroimages was performed by a neuroradiologist at the University of Virginia Health System. Software based on a polygonal area algorithm, which was developed at the same university, was used for volumetric assessment of outcome without a stereotactic frame. The margin of error associated with this method is Ϯ 7% for lesions smaller than 1 cm . Local tumor control was defined as either cessation of growth, shrinkage, or disappearance of the treated lesion based on the neuroimaging.
Evaluation of Neuroimages
Magnetic resonance imaging or CT studies obtained at the time of treatment were retrospectively reviewed for mass effect, enhancement pattern, and percentage of necrosis in 37 patients (67 treated lesions). Mass effect was classified as none, mild (effacement of local sulci), moderate (effacement of adjacent ventricle and sulci), or severe (midline and/or uncal herniation). Enhancement patterns were classified as homogeneous (uniform enhancement of the entire lesion), heterogeneous (any area of nonhomogeneous enhancement), or ring enhancing (thin rim of contrast enhancement surrounding a central nonenhancing, low signal intensity area). The amount of necrosis was scored as none, less than 50%, or 50% or greater.
Statistical Analysis
The median duration of survival was calculated using the Kaplan-Meier method and survival time was calculated from the date of the first GKS. Univariable and multivariable analyses were performed using the Cox proportional hazards model to study the effects of 13 independent variables on the length of survival and the extent of local control. The S-Plus 2000 software program (Insightful Corp., Seattle, WA) was used to perform the statistical analysis.
Results
Imaging Analysis
Follow-up imaging after GKS was not available for 10 patients because they died before the first follow-up imaging study was scheduled to take place, 3 months after the date of treatment. At the time of treatment the mean volume of each lesion was 4.1 cm 3 and the median tumor volume was 1.5 cm 3 . At the time of follow-up review the mean tumor volume was 2.6 cm 3 and the median volume was 0.74 cm 3 . Tumor volume at the time of treatment or after treatment did not correlate with the duration of survival or time to local treatment failure. The median total volume of all lesions in each patient at the time of treatment was 3.43 cm 3 , whereas after treatment it was 2.4 cm 3 . The total volume of all lesions was not associated with survival or time to local treatment failure. In 12 patients new lesions appeared outside the treated area. These patients survived a median of 16 months, whereas patients in whom there was no recurrence outside the treated area survived a median of 22 months (not statistically significant).
Magnetic resonance or CT images obtained at the time of treatment were retrospectively reviewed in 37 patients with 67 treated lesions based on the definitions listed earlier. Of the 67 treated lesions, 36 (54%) did not produce any mass effect on surrounding tissue, whereas 21 (31%), eight (12%), and two (3%) lesions produced a mild, moderate, and severe mass effect, respectively. Only six lesions (9%) were classified as ring-enhancing lesions; 30 (45%) were homogeneous and 31 (46%) were heterogeneous. With respect to the amount of necrosis, 34 lesions (51%) were scored as having no necrosis, 16 (24%) as having less than 50% necrosis, and 17 (25%) as having greater than 50% necrosis. There was no association between the mass effect, enhancement patterns, or the amount of necrosis at the time of treatment and the duration of survival or local tumor control.
Patient Survival
The overall median duration of survival from the date of GKS was calculated as being 13 months (95% CI 7-16 months) by using the Kaplan-Meier method (Fig. 1) . Patients with a higher KPS score survived longer: those with a KPS score of 80, 90, and 100 survived a median of 12.5, 13, and 16.5 months, respectively. Patients with solitary lesions survived a median of 17 months, whereas patients with multiple metastases survived a median of 13 months. The SIR, developed by Weltman, et al., 8 for use in patients with brain metastases, accounts for five prognostic factors (patient age, tumor size, number of lesions, location, and KPS score); the highest possible score is 10, whereas the lowest is 0. After assigning patients with scores of 8 to 10, 4 to 7, and 0 to 3 to separate groups, we found that the median duration of survival was 21, 8, and 3 months for each of the three groups, respectively. The univariable Cox regression analysis revealed that a single lesion (p = 0.03), a high KPS score (p = 0.0009), and a high SIR (p = 0.00033) were predictive of survival. A multivariable analysis in which seven variables were examined showed that a high KPS score (p = 0.006), a high SIR (p = 0.014), and advanced age (p = 0.038) were predictive of survival ( Table 3) . The 1-, 2-, 3-, and 5-year survival rates were 49, 23, 12, and 2%, respectively.
Local Control of Tumor
The overall median time to local treatment failure was 10 months (95% CI 6-14 months) after GKS, as determined using the Kaplan-Meier method. Patients with single lesions experienced local treatment failure at a median of 13 months, whereas those with multiple lesions experienced local failure at a median of 7 months. The univariable Cox regression analysis demonstrated that single lesions were associated with a significantly longer time to local treatment failure (p = 0.035). Patients with a KPS score of 80 experienced local failure at a median of 10 months, whereas those with a KPS score of 100 faced a local treatment failure of 16 months post-GKS. After assigning patients with an SIR of 8 to 10, 4 to 7, and 0 to 3 to separate groups, we found median times of 14, 8, and 4 months until local treatment failure, respectively. A multivariable analysis of 12 variables showed that a higher KPS score (p = 0.00024) and SIR (p = 0.036), and patients who had received chemotherapy for their intracranial lesions (p = 0.017) experienced significantly longer times to local treatment failure. The 6-month, 1-year, and 2-year local control rates were 52, 37, and 11%, respectively (Table 3 ). All patients who experienced treatment failures were again treated with GKS.
Discussion
The management of breast carcinoma that has metastasized to the brain includes chemotherapy, WBRT, resection, and stereotactic radiosurgery. The role of chemotherapy in the treatment of this disease has yet to be established. The use of WBRT as the sole treatment for intracranial lesions provides a median survival of up to 4 months after treatment.
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Resection has been shown to offer patients a median survival time of 14 and 16 months in studies conducted by Wronski and colleagues 10 and Pieper, et al., 6 respectively. Wronski and colleagues found that only postoperative WBRT and a positive estrogen or progesterone receptor status were predictive of survival. Pieper, et al., found that age, menopause status, postoperative WBRT, preoperative systemic disease status, and preoperative neurologiccal status were predictive of survival. Nevertheless, comparisons between the present study and surgical studies must be made while keeping in mind the inherent selection criteria that drive patterns of referral to surgery as opposed to radiosurgery.
One key factor is the number of metastases. Only 23% of patients in the series conducted by Wronski and colleagues 10 and 13% of those in the series undertaken by Pieper, et al., 6 had multiple metastases, compared with 60% of patients in the present study.
Thirty-four percent of patients in the report by Wronski and colleagues 10 had neurological deficits before they underwent resection. In the present study, 50% of the tumors were located in the brainstem and 95% of the patients exhibited neurological symptoms before they underwent GKS. The retrospective nature of the analysis precluded a detailed analysis of the course of existing neurological deficits at the time of the treatment. It is notable that for lesions in deep locations and in the brainstem, the increases in morbidity and mortality associated with craniotomy cannot be ignored.
The location of the lesion has a significant bearing on the relative importance of performing surgery or radiosurgery in a given patient. In the series described by Wronski and colleagues and Pieper, et al., only patients with surgically accessible brain metastases were considered for resection. In the former series there were 12 patients with infratentorial lesions; the median survival time for these patients was 10.9 months, whereas that for the remaining patients was 14.5 months. By contrast, two thirds of the patients in the present series harbored tumors in the infratentorial compartment and 12% were in the brainstem. There were no radiosurgery-related complications observed in this population.
In the study conducted by Pieper, et al., 6 patients were excluded if they had undergone previous treatment for their brain lesions, and resection was performed less than 2 weeks after diagnosis of brain metastases. In the present study, on the other hand, WBRT failed in 70% of the patients who likely represented a poorer prognostic subset. In addition, 9% of patients had undergone resection before GKS was performed.
In a comparison of the series conducted by Wronski and colleagues 10 and Pieper, et al., 6 therefore, one must keep in mind that the surgical outcome for patients in the present series is likely to have been worse than the general results of surgery reported in the literature. This puts the observed local tumor control rates in perspective with the often higher overall control rates reported for patients with other types of primary tumors and the choice of surgery compared with GKS for these patients.
Radiosurgery in the treatment of breast carcinoma that has metastasized to the brain is effective in prolonging overall survival. Gamma knife surgery resulted in a median survival of 13 months from the date of radiosurgery. In a study population similar to that in the present study, a case series of 30 patients with 58 metastatic lesions, Firlik, et al., 3 reported a median survival time of 13 months after treatment. Both studies included nearly equal proportions of patients with multiple lesions: 53% in the study conducted by Firlik, et al., and 60% in the present study. Furthermore, 70% of patients in both studies received WBRT before they underwent GKS.
Amendola and associates 1 and Lederman, et al., 5 also studied intracranial breast cancer lesions and found a 7.8-
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Gamma knife surgery for cerebral breast cancer metastases and 7.5-month median duration of survival after treatment, respectively. In those studies, however, the patient populations and tumor characteristics were different from those in the present study. A mean of eight sites per patient (68 patients with 518 treated lesions) were treated in the study of Amendola and associates. In the study conducted by Lederman, et al., linear accelerator surgery was performed in a cohort of 60 patients (246 treated lesions) in which 43 patients also received fractionated stereotactic radiotherapy (Table 4) . In the present study, a higher KPS score, advanced patient age, and a higher SIR were found to correlate with prolonged survival. The SIR was developed by Weltman, et al., 8 for use in patients with brain metastases and is based on the patient's age, KPS score, systemic disease status, number of brain lesions, and largest brain lesion volume. In the present study we found the SIR to be the most sensitive predictor of survival. In the study by Firlik, et al., 3 on the other hand, only the presence of a solitary metastasis was found to be predictive of survival.
221
In the present study, the performance of WBRT prior to GKS did not afford patients any additional survival time or local tumor control. The majority of patients received WBRT and underwent GKS as a planned management strategy. The minority (five patients) who did undergo GKS as a salvage treatment for WBRT failures did not fare differently from the rest, although it should be remarked that this study was not designed nor powered to examine this difference. In a study on intracranial breast carcinoma conducted by Amendola and associates, 1 38 patients underwent GKS after WBRT failed to manage the disease and another 30 patients underwent only GKS; the use of WBRT afforded no survival advantage to patients. Sneed, et al., 7 concluded that withholding WBRT prior to treatment of intracranial metastases with GKS did not significantly affect the duration of survival or local tumor control, a finding that we can confirm on the basis of the five patients in this series who met this description.
Magnetic resonance or CT images obtained at treatment in 37 patients with 67 treated lesions were retrospectively reviewed, and no association between mass effect, enhancement patterns, or amount of necrosis and the duration of survival or local control was found. Goodman, et al., 4 found that on the day of radiosurgery the pattern of enhancement representing brain metastases was a significant predictor of freedom from progression and indicates that lesions with regions of low-signal "necrosis," compared with homogeneously enhancing lesions, may in fact contain additional radioresistant tumor cells. Because of our small sample size, these differences were not seen in our study.
Conclusions
Gamma knife surgery is an effective form of treatment in patients with intracranial metastatic lesions from breast carcinoma. Radiosensitizing agents will be used in conjuction with GKS to augment survival and local tumor control in the future. Proper prospective, randomized controlled studies are needed to help elucidate which patients will benefit from this procedure. The role of WBRT in the management of limited numbers of brain metastases remains uncertain. The likelihood that a well-designed prospective randomized trial powered to answer this question will ever be done remains low.
